-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News, March 11 On March 10, Kelun, Qilu, and Shenyang Hongqi Pharmaceuticals submitted enzalutamide soft capsule listing applications for generic 4 types.
The product has not been approved for the first imitation in China.
Enzalutamide (Enzalutamide) is an androgen receptor inhibitor with global sales exceeding US$4 billion in 2019.
The product has not been approved for the first imitation in China.
Enzalutamide (Enzalutamide) is an androgen receptor inhibitor with global sales exceeding US$4 billion in 2019.
Source: CDE official website
Enzalutamide is an androgen receptor inhibitor jointly developed by Astellas and Medivation.
It was first approved by the FDA in August 2012 for the treatment of advanced castration-resistant prostate cancer.
In August 2016, Pfizer acquired Medivation for US$14 billion and included this blockbuster drug in the bag.
It was first approved by the FDA in August 2012 for the treatment of advanced castration-resistant prostate cancer.
In August 2016, Pfizer acquired Medivation for US$14 billion and included this blockbuster drug in the bag.
Global sales of enzalutamide
Source: Mynet.
com's sales database of multinational listed companies
com's sales database of multinational listed companies
With the clinical benefit of prolonging the survival period of 5 months and the advantage that the clinical use does not need to be combined with the glucocorticoid prednisone, enzalutamide quickly opened up the market after its listing.
In 2019, the global sales exceeded 4 billion US dollars, a substantial Abiraterone, which surpassed Johnson & Johnson, became a well-deserved super blockbuster in the prostate cancer market.
In 2019, the global sales exceeded 4 billion US dollars, a substantial Abiraterone, which surpassed Johnson & Johnson, became a well-deserved super blockbuster in the prostate cancer market.
Astellas' enzalutamide was approved to enter the domestic market in November 2019, and its compound patent is expected to expire in 2026 at the earliest.
In November 2018, Xingtai Pharmaceutical, a subsidiary of Fosun Pharma , successfully challenged the invention patent (No.
ZL200680025545.
1) of the product "Diarylhydantoin compound", which is the application of enzalutamide imitation for other domestic applications.
Pharmaceutical companies have eliminated the patent barrier.
In November 2018, Xingtai Pharmaceutical, a subsidiary of Fosun Pharma , successfully challenged the invention patent (No.
ZL200680025545.
1) of the product "Diarylhydantoin compound", which is the application of enzalutamide imitation for other domestic applications.
Pharmaceutical companies have eliminated the patent barrier.
New classification of enzalutamide production status
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
According to data from Minai.
com, there are currently 4 domestic companies that have submitted enzalutamide listing applications under the new classification, including Hausen, Kelun, Qilu, and Shenyang Hongqi Pharmaceutical.
Who will be the first imitation? Mi Nei.
com will continue to pay attention.
com, there are currently 4 domestic companies that have submitted enzalutamide listing applications under the new classification, including Hausen, Kelun, Qilu, and Shenyang Hongqi Pharmaceutical.
Who will be the first imitation? Mi Nei.
com will continue to pay attention.
Source: Minet database, CDE official website
Note: The statistics are as of March 10, if there are any omissions, please correct me!
Medical Network News, March 11 On March 10, Kelun, Qilu, and Shenyang Hongqi Pharmaceuticals submitted enzalutamide soft capsule listing applications for generic 4 types.
The product has not been approved for the first imitation in China.
Enzalutamide (Enzalutamide) is an androgen receptor inhibitor with global sales exceeding US$4 billion in 2019.
The product has not been approved for the first imitation in China.
Enzalutamide (Enzalutamide) is an androgen receptor inhibitor with global sales exceeding US$4 billion in 2019.
Source: CDE official website
Enzalutamide is an androgen receptor inhibitor jointly developed by Astellas and Medivation.
It was first approved by the FDA in August 2012 for the treatment of advanced castration-resistant prostate cancer.
In August 2016, Pfizer acquired Medivation for US$14 billion and included this blockbuster drug in the bag.
It was first approved by the FDA in August 2012 for the treatment of advanced castration-resistant prostate cancer.
In August 2016, Pfizer acquired Medivation for US$14 billion and included this blockbuster drug in the bag.
Global sales of enzalutamide
Source: Mynet.
com's sales database of multinational listed companies
com's sales database of multinational listed companies
With the clinical benefit of prolonging the survival period of 5 months and the advantage that the clinical use does not need to be combined with the glucocorticoid prednisone, enzalutamide quickly opened up the market after its listing.
In 2019, the global sales exceeded 4 billion US dollars, a substantial Abiraterone, which surpassed Johnson & Johnson, became a well-deserved super blockbuster in the prostate cancer market.
In 2019, the global sales exceeded 4 billion US dollars, a substantial Abiraterone, which surpassed Johnson & Johnson, became a well-deserved super blockbuster in the prostate cancer market.
Astellas' enzalutamide was approved to enter the domestic market in November 2019, and its compound patent is expected to expire in 2026 at the earliest.
In November 2018, Xingtai Pharmaceutical, a subsidiary of Fosun Pharma , successfully challenged the invention patent (No.
ZL200680025545.
1) of the product "Diarylhydantoin compound", which is the application of enzalutamide imitation for other domestic applications.
Pharmaceutical companies have eliminated the patent barrier.
In November 2018, Xingtai Pharmaceutical, a subsidiary of Fosun Pharma , successfully challenged the invention patent (No.
ZL200680025545.
1) of the product "Diarylhydantoin compound", which is the application of enzalutamide imitation for other domestic applications.
Pharmaceutical companies have eliminated the patent barrier.
New classification of enzalutamide production status
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
According to data from Minai.
com, there are currently 4 domestic companies that have submitted enzalutamide listing applications under the new classification, including Hausen, Kelun, Qilu, and Shenyang Hongqi Pharmaceutical.
Who will be the first imitation? Mi Nei.
com will continue to pay attention.
com, there are currently 4 domestic companies that have submitted enzalutamide listing applications under the new classification, including Hausen, Kelun, Qilu, and Shenyang Hongqi Pharmaceutical.
Who will be the first imitation? Mi Nei.
com will continue to pay attention.
Source: Minet database, CDE official website
Note: The statistics are as of March 10, if there are any omissions, please correct me!
Medical Network News, March 11 On March 10, Kelun, Qilu, and Shenyang Hongqi Pharmaceuticals submitted enzalutamide soft capsule listing applications for generic 4 types.
The product has not been approved for the first imitation in China.
Enzalutamide (Enzalutamide) is an androgen receptor inhibitor with global sales exceeding US$4 billion in 2019.
The product has not been approved for the first imitation in China.
Enzalutamide (Enzalutamide) is an androgen receptor inhibitor with global sales exceeding US$4 billion in 2019.
Source: CDE official website
Enzalutamide is an androgen receptor inhibitor jointly developed by Astellas and Medivation.
It was first approved by the FDA in August 2012 for the treatment of advanced castration-resistant prostate cancer.
In August 2016, Pfizer acquired Medivation for US$14 billion and included this blockbuster drug in the bag.
It was first approved by the FDA in August 2012 for the treatment of advanced castration-resistant prostate cancer.
In August 2016, Pfizer acquired Medivation for US$14 billion and included this blockbuster drug in the bag.
Global sales of enzalutamide
Source: Mynet.
com's sales database of multinational listed companies
com's sales database of multinational listed companies
With the clinical benefit of prolonging the survival period of 5 months and the advantage that the clinical use does not need to be combined with the glucocorticoid prednisone, enzalutamide quickly opened up the market after its listing.
In 2019, the global sales exceeded 4 billion US dollars, a substantial Abiraterone, which surpassed Johnson & Johnson, became a well-deserved super blockbuster in the prostate cancer market.
In 2019, the global sales exceeded 4 billion US dollars, a substantial Abiraterone, which surpassed Johnson & Johnson, became a well-deserved super blockbuster in the prostate cancer market.
Astellas' enzalutamide was approved to enter the domestic market in November 2019, and its compound patent is expected to expire in 2026 at the earliest.
In November 2018, Xingtai Pharmaceutical, a subsidiary of Fosun Pharma , successfully challenged the invention patent (No.
ZL200680025545.
1) of the product "Diarylhydantoin compound", which is the application of enzalutamide imitation for other domestic applications.
Pharmaceutical companies have eliminated the patent barrier.
Pharmaceutical Pharmaceutical Pharmaceutical Enterprise Enterprise EnterpriseIn November 2018, Xingtai Pharmaceutical, a subsidiary of Fosun Pharma , successfully challenged the invention patent (No.
ZL200680025545.
1) of the product "Diarylhydantoin compound", which is the application of enzalutamide imitation for other domestic applications.
Pharmaceutical companies have eliminated the patent barrier.
New classification of enzalutamide production status
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
According to data from Minai.
com, there are currently 4 domestic companies that have submitted enzalutamide listing applications under the new classification, including Hausen, Kelun, Qilu, and Shenyang Hongqi Pharmaceutical.
Who will be the first imitation? Mi Nei.
com will continue to pay attention.
com, there are currently 4 domestic companies that have submitted enzalutamide listing applications under the new classification, including Hausen, Kelun, Qilu, and Shenyang Hongqi Pharmaceutical.
Who will be the first imitation? Mi Nei.
com will continue to pay attention.
Source: Minet database, CDE official website
Note: The statistics are as of March 10, if there are any omissions, please correct me!
